Recent studies revealed that multiple factors including MGMT mutation, tumor immune microenvironment, inflammasome and PI3K/Akt pathways could contribute to individualized TMZ efficacy [25–27], whereas there still lack of strategies to increase the chemotherapy sensitivity. Here, AKT1 is linked to neoplasm.